InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
IPO Year: 2017
Exchange: NASDAQ
Website: inflarx.de
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/5/2023 | $8.00 | Neutral → Buy | Guggenheim |
2/28/2022 | Buy → Neutral | Guggenheim | |
11/8/2021 | $14.00 → $15.00 | Strong Buy | Raymond James |
10/28/2021 | $14.00 | Outperform → Strong Buy | Raymond James |
8/6/2021 | $11.00 → $10.00 | Outperform | Raymond James |
8/6/2021 | $2.80 → $2.50 | Underperform | Credit Suisse |
JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx. Mr. Medina brings over 25 years of extensive experience across the life sciences sector and capital markets, including in the areas of investor relations, communications and equity research. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: "We are delighted to welcome Jan to our team. His experience, proven track record and deep network with investors and capital mark
Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical industry in drug developmentDr. Chong to lead clinical development of InflaRx's portfolio of C5a/C5aR inhibitors JENA, Germany, June 28, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a clinical-stage biopharmaceutical company commercializing and developing anti-inflammatory therapeutics that target the complement system, today announced the appointment of Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023. Dr. Chong is a medical doctor with extensive experience in the pharmaceutical industry, including leadership roles in clinical development, medical affai
HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $8 price target.
DSMB Recommends Continuation without Modification for Third TimeSafety Review Included 395 PatientsInterim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event RateLow Event Rate Suggests Potential for Prolonged SurvivalRapid Enrollment Positions Company for Enrollment Completion by Q1 2025; Earlier Than Expected
HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $8 price target.
HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $8 price target.
InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.22) by 15.91 percent. The company reported quarterly sales of $39.138 thousand which missed the analyst consensus estimate of $1.268 million by 96.91 percent.
HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $8 price target.
JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of preclinical data for the company's novel oral C5aR inhibitor, INF904, at the 2024 European Meeting on Complement in Human Diseases (EMCHD) being held in Lübeck, Germany, September 2 – 6, 2024. Members of InflaRx leadership also participated in a satellite symposium highlighting the role of the C5a/C5aR1 axis in driving inflammation and served as the biopharma industry representative on a panel focused on the relevance of targeting C3 and C5. InflaRx also hosted a lunch s
JENA, Germany, Aug. 27, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in two investor conferences in September 2024. Details are as follows: H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 9-11, 2024 in New York, NY InflaRx's on-demand virtual presentation for the conference will be available beginning on September 9th. InflaRx will also participate in one-on-one investor meetings in New York City on September 10th. 2024 Cantor Global Healthcare ConferenceSeptember 17-19, 2024 in New York, NY InflaRx will conduct a f
Hosted research and development (R&D) event focused on the differentiation of INF904 and its potential in addressing significant unmet needs in inflammation & immunology (I&I)Initiation of a Phase 2a study with INF904 in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by year-end 2024First Phase 2a data readout for INF904 expected in the summer of 2025, with Phase 2b trial initiation expected in 2025Interim analysis for vilobelimab Phase 3 trial in pyoderma gangrenosum (PG) expected in 2025, and by year-end 2024 InflaRx anticipates providing greater precision on this timelineGOHIBIC (vilobelimab) selected for first Biomedical Advanced Research and Development A
JENA, Germany, Aug. 01, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its second quarter 2024 financial and operating results on August 8, 2024, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory me
JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced it will present preclinical data on the company's novel oral C5aR inhibitor, INF904, at the 2024 European Meeting on Complement in Human Diseases (EMCHD) being held in Lübeck, Germany, September 2 – 6, 2024. In addition to two poster presentations, InflaRx representatives will participate in a C5a/C5aR-focused panel discussion as well as speak at a satellite symposium. EMCHD 2024 will focus on emerging developments in the complement field with a goal of translating basic scientific advancements
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, as one of three investigational therapies to be assessed in a Phase 2 clinical platform study exploring potential new options for the treatment of acute respiratory distress syndrome (ARDS). Prof. Niels C. Riedemann, Chief Executive Officer and Founder of In
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & immunology (I&I) more broadlyAdditional details provided on INF904 Phase 2a trial design in moderate-to-severe CSU and HS, with study initiation expected by the calendar year-end of 2024 and a goal of generating additional safety and pharmacokinetic (PK) data, and showing meaningful clinical benefitINF904 Phase 2a data expected in summer 2025, with Phase 2b trial initiation expected in 2025Commercial assess
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held from May 17-22, 2024 in San Diego. InflaRx is presenting a poster at the thematic poster session at the ATS conference today from 11:30 AM PT / 2:30 PM ET to 1:15 PM PT / 4:15 PM ET. The poster is titled, "Vilobelimab in Combination with Tocilizumab or Baricitinib Dramatically Improves Mortality in Critically Ill COVID-19 Patients" and is being presented during the "ARDS and Acute Respiratory Failur
Virtual R&D event to be held on June 5, 2024 from 12:00 to 2:00 PM EDT – highlighting company plans for INF904 and the opportunity, the role of C5aR in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) and C5a/C5aR signaling in human inflammatory diseases INF904 multiple ascending dose (MAD) pharmacokinetic (PK) and pharmacodynamic (PD) data supporting best-in-class potential announced, and plans to initiate Phase IIa in CSU and HS by the end of 2024, with data availability anticipated in 2025Phase III vilobelimab pyoderma gangrenosum (PG) trial expected to have an interim analysis in 2025Cash, cash equivalents and marketable securities of €85.8 million, expected to fund
JENA, Germany, April 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2024 financial and operating results on May 8, 2024, before the market opens. No conference call is planned for the first quarter 2024 results. InflaRx also announced it will host a virtual research and development event on June 5, 2024. Guided by internationally renowned thought leaders, this event will focus on the planned development of our new oral small molecule C5aR inhibitor, INF904, and the role of C5aR in chronic spontaneous urticaria (CSU) and h
6-K - InflaRx N.V. (0001708688) (Filer)
424B5 - InflaRx N.V. (0001708688) (Filer)
6-K - InflaRx N.V. (0001708688) (Filer)
6-K - InflaRx N.V. (0001708688) (Filer)
6-K - InflaRx N.V. (0001708688) (Filer)
6-K - InflaRx N.V. (0001708688) (Filer)
6-K - InflaRx N.V. (0001708688) (Filer)
6-K - InflaRx N.V. (0001708688) (Filer)
6-K - InflaRx N.V. (0001708688) (Filer)
6-K - InflaRx N.V. (0001708688) (Filer)
Guggenheim upgraded InflaRx from Neutral to Buy and set a new price target of $8.00
Guggenheim downgraded InflaRx from Buy to Neutral
Raymond James reiterated coverage of InflaRx with a rating of Strong Buy and set a new price target of $15.00 from $14.00 previously
Raymond James upgraded InflaRx from Outperform to Strong Buy and set a new price target of $14.00
Raymond James reiterated coverage of InflaRx with a rating of Outperform and set a new price target of $10.00 from $11.00 previously
Credit Suisse reiterated coverage of InflaRx with a rating of Underperform and set a new price target of $2.50 from $2.80 previously
Credit Suisse reiterated coverage of InflaRx with a rating of Underperform and set a new price target of $2.80 from $3.50 previously
Raymond James reiterated coverage of InflaRx with a rating of Outperform and set a new price target of $11.00 from $12.00 previously
HC Wainwright & Co. reiterated coverage of InflaRx with a rating of Buy and set a new price target of $10.00 from $12.00 previously
Guggenheim upgraded InflaRx from Neutral to Buy
SC 13G - InflaRx N.V. (0001708688) (Subject)
SC 13G - InflaRx N.V. (0001708688) (Subject)
SC 13G/A - InflaRx N.V. (0001708688) (Subject)
SC 13G/A - InflaRx N.V. (0001708688) (Subject)
SC 13G - InflaRx N.V. (0001708688) (Subject)
SC 13G - InflaRx N.V. (0001708688) (Subject)
SC 13G/A - InflaRx N.V. (0001708688) (Subject)
JENA, Germany, Aug. 01, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its second quarter 2024 financial and operating results on August 8, 2024, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory me
JENA, Germany, April 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2024 financial and operating results on May 8, 2024, before the market opens. No conference call is planned for the first quarter 2024 results. InflaRx also announced it will host a virtual research and development event on June 5, 2024. Guided by internationally renowned thought leaders, this event will focus on the planned development of our new oral small molecule C5aR inhibitor, INF904, and the role of C5aR in chronic spontaneous urticaria (CSU) and h
JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company's anticipated development plans for INF904, InflaRx's orally available C5aR inhibitor with best-in-class potential. The Company will also publish its financial and operating results for the fourth quarter and full year 2023 on March 21, 2024, in advance of the call. To participate in the conference call, participants may pre-register here and will receive a dedicated link and d
MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days: Achieved ≥90% blockade of C5a-induced neutrophil activation over 14-day dosing periodAchieved favorable concentration-time profiles with target exposures of therapeutic potential Well tolerated with no safety signals of concern over entire dose range Company to advance INF904 into Phase II clinical developmentCompany to host a conference call today, January 4, 2024 at 8:30 a.m. EST/14:30 CET JENA, Germany, Jan. 04, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biotechnology company pioneering anti-inflam
SAD data confirm best-in-class potential for INF904 as orally administered C5aR inhibitor: Safety and tolerability with no signals of concern over entire dose rangePharmacokinetics (PK): favorable dose-proportional systemic exposure with overall PK profile confirming pre-clinical dataDesired blocking activity (>90%) of C5a-induced neutrophil activation at disease relevant C5a levels 24 hours post administration for doses of 30 mg to 240 mgINF904 can be formulated with drug strength of 30 mg per capsule Data from the ongoing multiple ascending dose (MAD) part of the study to be presented in early 2024Company to host a conference call today, September 11, 2023 at 8:30 am EDT/14:30 CEST JENA,
Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body's immune responseFDA granted EUA based on Phase III clinical trial results showing a significant relative reduction in 28-day all-cause mortality of 23.9% compared to placebo in critically ill invasively mechanically ventilated COVID-19 patientsInflaRx continues the dialogue with FDA to discuss next steps towards a Biologics License Application submission for full approvalEncouraging pre-submission meetings held with EMA in Europe; InflaRx plans to apply for full approval to treat critically ill COVID-19 patientsCompany to host a conference call tomo
Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show statistical significance on the pre-specified primary endpointPre-specified sensitivity analysis of the primary endpoint results in p-values of <0.05 in three out of four planned analyses in favor of vilobelimab treatment43% relative reduction in 28-day all-cause mortality detected in pre-specified subgroup analysis in Western European patients comparing vilobelimab to placebo treatment (n=209, p-value=0.014)Additional pre-specified subgroup analyses in patients with more severe disease confirm treatment benefit for vilobelimab, resulting in p-value
Presentation at J.P. Morgan Healthcare Conference on January 13thCorporate presentation for H.C. Wainwright BioConnect Conference available online starting January 10thCompany to host virtual R&D Event on vilobelimab in Hidradenitis Suppurativa on February 3rd JENA, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at several investor events. 40th Annual J.P. Morgan Healthcare Conference: Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, will give a corporate presentation on Thursday
Phase III study to include a new primary endpoint, the modified HiSCRNew primary endpoint and Phase III trial design to be discussed in detail at virtual R&D event on February 3rdPhase III program to focus on HS patients with active draining tunnels and will start enrolling patients in Q2 JENA, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the initiation of the Phase III program with vilobelimab in hidradenitis suppurativa (HS) patients with active draining tunnels. The new primary endpoint, called modified HiSCR (Hidradenitis
6 out of 7 patients (85.7%) showed clinical remission (PGA score ≤ 1) and closure of target ulcer in the highest dose cohortTreatment was well tolerated; no dose-related adverse events observedFinal post treatment observational data will be available in the first half of 2022InflaRx to host conference call today at 8:30 am EDT / 2:30 pm CEST JENA, Germany, Oct. 27, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces positive data from the third cohort of patients in the Phase IIa open-label study with vilobelimab in Pyoderma Gangraenosum (PG). "We are happy